Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evolocumab - Amgen

Next Previous
Drug Profile

Evolocumab - Amgen

Alternative Names: AMG-145; Repatha

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Amgen Astellas BioPharma; University Hospital Inselspital
  • Class Anti-ischaemics; Antihyperlipidaemics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke
  • Phase III Coronary artery disease; Dyslipidaemias; Hyperlipidaemia

Most Recent Events

  • 11 Nov 2023 Interim efficacy data from a phase III trial in hypercholesterolaemia presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
  • 11 Nov 2023 Safety and efficacy data from a phase III BERSON trial in Hyperlipidaemia presented at the at the American Heart Association Scientific Sessions 2023 (AHA-2023)
  • 10 Nov 2023 Efficacy data from a phase III FOURIER-OLE trial in patients with cardiovascular disease released by Amgen
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top